Enlivex Therapeutics Ltd (ENLV)

$1.21 -0.05 (-3.97%)
Market Cap 29.80M
Revenue (ttm) 0.00
Net Income (ttm) -15.01M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 67,200
Avg Vol 67,162
Day's Range N/A - N/A
Shares Out 23.65M
Stochastic %K 78%
Beta 0.74
Analysts Strong Sell
Price Target $10.00

Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 620 8072
Address:
14 Einstein Street, Ness Ziona, Israel
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 26 at 10:47 AM
$ENLV
0 · Reply
Nicks_pics
Nicks_pics Jun. 24 at 4:28 PM
$ENLV Biggest dip buy in my history of dip buying. Going to be a great 2025.
0 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 23 at 8:22 PM
$ENLV Pacho bought a good bunch today. Israel and the US is fighting its enemies: soon pace in Israel so ENLV may flourish.
1 · Reply
mbelect
mbelect Jun. 23 at 7:48 PM
$ENLV still shit 79% in red from 5 years a go.
0 · Reply
cotrusadrian
cotrusadrian Jun. 23 at 3:25 PM
$ENLV Any ideas what might be the leak?
1 · Reply
Candace_Bk
Candace_Bk Jun. 23 at 2:06 PM
$ENLV super quiet on this board… any PT on this?
0 · Reply
jacksonjohn750
jacksonjohn750 Jun. 17 at 4:33 AM
$ENLV LIKE YOU DID, I SEE WHY YOU SUPPORT THEM
1 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 16 at 8:28 PM
$ENLV Pacho is in again. Thanks for 5% profit already. Let's go for 2 dollars.
1 · Reply
Nicks_pics
Nicks_pics Jun. 16 at 3:04 PM
$ENLV Added this morning. IYKYK
1 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 15 at 12:37 AM
$ENLV Getting ready to invest big again. Supporting Enlivex = building on Israels future 🇮🇱
1 · Reply
Latest News on ENLV
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Jun 10, 2025, 8:30 AM EDT - 16 days ago

Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology

Enlivex Selected to Present at Israeli BioMed 2025 Conference

May 20, 2025, 8:00 AM EDT - 5 weeks ago

Enlivex Selected to Present at Israeli BioMed 2025 Conference

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Apr 23, 2025, 8:30 AM EDT - 2 months ago

Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Apr 21, 2025, 8:30 AM EDT - 2 months ago

Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Apr 3, 2025, 8:00 AM EDT - 3 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Mar 17, 2025, 8:00 AM EDT - 3 months ago

Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Mar 4, 2025, 4:30 PM EST - 4 months ago

Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Mar 3, 2025, 8:22 AM EST - 4 months ago

Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Feb 18, 2025, 6:20 AM EST - 4 months ago

Enlivex Issues Urgent Statement on Fraudulent News Dissemination

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jan 10, 2025, 9:00 AM EST - 5 months ago

Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Dec 11, 2024, 8:30 AM EST - 7 months ago

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Dec 5, 2024, 10:49 AM EST - 7 months ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Nov 26, 2024, 10:15 AM EST - 7 months ago

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nov 14, 2024, 8:00 AM EST - 8 months ago

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Oct 30, 2024, 8:00 AM EDT - 8 months ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Sep 24, 2024, 8:30 AM EDT - 9 months ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 30, 2024, 9:00 AM EDT - 10 months ago

GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GP

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 19, 2024, 9:00 AM EDT - 1 year ago

Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Jun 17, 2024, 8:00 AM EDT - 1 year ago

Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

May 29, 2024, 4:15 PM EDT - 1 year ago

Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

May 28, 2024, 8:12 AM EDT - 1 year ago

Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Apr 16, 2024, 7:50 AM EDT - 1 year ago

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Apr 11, 2024, 2:58 PM EDT - 1 year ago

Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Apr 11, 2024, 8:05 AM EDT - 1 year ago

Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Mar 22, 2024, 10:50 AM EDT - 1 year ago

Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

UMAC

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Feb 26, 2024, 8:30 AM EST - 1 year ago

Enlivex Receives Regulatory Authorization From Israel's Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Feb 21, 2024, 8:30 AM EST - 1 year ago

Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Jan 17, 2024, 8:00 AM EST - 1 year ago

Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Dec 20, 2023, 8:00 AM EST - 1 year ago

Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Jul 31, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With Sepsis

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Jun 6, 2023, 8:00 AM EDT - 2 years ago

Enlivex to Present at the 2023 Jefferies Healthcare Conference

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

May 31, 2023, 8:04 AM EDT - 2 years ago

Enlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene Therapy

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

May 8, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Apr 19, 2023, 8:00 AM EDT - 2 years ago

Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy

Enlivex Appoints Andrew Singer to its Board of Directors

Apr 17, 2023, 8:00 AM EDT - 2 years ago

Enlivex Appoints Andrew Singer to its Board of Directors

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Apr 14, 2023, 9:40 AM EDT - 2 years ago

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Apr 12, 2023, 10:45 AM EDT - 2 years ago

Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

Apr 4, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

Apr 3, 2023, 8:00 AM EDT - 2 years ago

Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Mar 20, 2023, 8:00 AM EDT - 2 years ago

Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Feb 15, 2023, 8:00 AM EST - 2 years ago

Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Jan 25, 2023, 8:37 AM EST - 2 years ago

Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

Dec 5, 2022, 8:00 AM EST - 2 years ago

Enlivex Announces Third Quarter 2022 Financial Results and Provides a Business Update

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Nov 15, 2022, 8:00 AM EST - 2 years ago

Enlivex Announces Dosing of the First Patient in Phase I/II Trial Evaluating Allocetra Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

Oct 3, 2022, 8:13 AM EDT - 2 years ago

Enlivex to Present at the 4th Macrophage-Directed Therapies Summit

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Sep 30, 2022, 2:08 AM EDT - 2 years ago

Enlivex Therapeutics: A Very Enticing Early-Stage Biotech

Enlivex to Present at Upcoming Investor and Media Conferences

Sep 13, 2022, 8:00 AM EDT - 3 years ago

Enlivex to Present at Upcoming Investor and Media Conferences

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Sep 12, 2022, 8:00 AM EDT - 3 years ago

Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

Aug 29, 2022, 8:00 AM EDT - 3 years ago

Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Aug 24, 2022, 8:00 AM EDT - 3 years ago

Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial

Pacho_Unlimited1
Pacho_Unlimited1 Jun. 26 at 10:47 AM
$ENLV
0 · Reply
Nicks_pics
Nicks_pics Jun. 24 at 4:28 PM
$ENLV Biggest dip buy in my history of dip buying. Going to be a great 2025.
0 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 23 at 8:22 PM
$ENLV Pacho bought a good bunch today. Israel and the US is fighting its enemies: soon pace in Israel so ENLV may flourish.
1 · Reply
mbelect
mbelect Jun. 23 at 7:48 PM
$ENLV still shit 79% in red from 5 years a go.
0 · Reply
cotrusadrian
cotrusadrian Jun. 23 at 3:25 PM
$ENLV Any ideas what might be the leak?
1 · Reply
Candace_Bk
Candace_Bk Jun. 23 at 2:06 PM
$ENLV super quiet on this board… any PT on this?
0 · Reply
jacksonjohn750
jacksonjohn750 Jun. 17 at 4:33 AM
$ENLV LIKE YOU DID, I SEE WHY YOU SUPPORT THEM
1 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 16 at 8:28 PM
$ENLV Pacho is in again. Thanks for 5% profit already. Let's go for 2 dollars.
1 · Reply
Nicks_pics
Nicks_pics Jun. 16 at 3:04 PM
$ENLV Added this morning. IYKYK
1 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 15 at 12:37 AM
$ENLV Getting ready to invest big again. Supporting Enlivex = building on Israels future 🇮🇱
1 · Reply
mbelect
mbelect Jun. 13 at 6:53 PM
$ENLV shitmixedwithgarbage
0 · Reply
TeenageMutantNinjaTrader
TeenageMutantNinjaTrader Jun. 13 at 11:35 AM
$ENLV seeing less penny stock commercials on cnbc lately. Thank god
0 · Reply
mbelect
mbelect Jun. 11 at 7:52 PM
$ENLV today is another day that enlv is shit. negative 80% from 3 years ago
0 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 Jun. 10 at 8:20 PM
$ENLV Pacho stands with Israel, no matter what. That’s why Pacho invests in Jewish companies like Enlivex. Together we can!
1 · Reply
mbelect
mbelect Jun. 10 at 7:06 PM
$ENLV today is another day ENLV is shit. - 80% since 3 years ago .
0 · Reply
mbelect
mbelect Jun. 9 at 6:22 PM
$ENLV today is another day that ENLV is shit
0 · Reply
mbelect
mbelect Jun. 9 at 6:20 PM
$ENLV maybe they should invest more into crypto. we might have better chances on recovering some money from our losses
0 · Reply
mbelect
mbelect Jun. 9 at 6:19 PM
$ENLV garbage
0 · Reply
Pacho_Unlimited1
Pacho_Unlimited1 May. 29 at 10:48 PM
$ENLV Pacho is preparing to take a small position in ENLV again. Timing is everything. Hasta la vista brethren!
3 · Reply
mbelect
mbelect May. 28 at 3:11 PM
$ENLV the biggest loss of all my investments. I believed in this company invested and now down 80k. full of promises and lies. the stock keeps dipping for the past 10 years since conception.
1 · Reply
Parched_River_Capital
Parched_River_Capital May. 23 at 5:06 PM
$ENLV amazing this pos isn't .01 yet
2 · Reply
TimRegan_WTR
TimRegan_WTR May. 22 at 5:49 PM
$ENLV
0 · Reply